Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON-RLS: Intravenous ferric carboxymaltose for drug-resistant restless legs syndrome
2026-525613-31-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ferric carboxymaltose in restless legs syndrome (RLS) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Change in IRLSSG-Q score from baseline to 3 months. Planned start May 2026; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2026-525613-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525613-31-00.